pCR proves valid surrogate endpoint.
Results from the randomized, phase III NeoALTTO trial, presented at the 2013 San Antonio Breast Cancer Symposium in December, support the idea that pathologic complete response is a valid surrogate endpoint for the effectiveness of long-term neoadjuvant treatment of breast cancer.